精準醫療發展前沿：類器官
Frontiers of Precision Medicine: Organoids
On Feb. 25th, we are excited to have Dr. Eva Jingyi Liu, Senior Manager, Merck Innovation Hub China and Dr. Xianglong Zhao from Bio-X Institutes of Shanghai Jiao Tong University as our panel discussion speakers to discuss the application of organoids in tumor drug development and precision clinical medicine. Merck will also introduce their Accelerator program and answer questions regarding the program recruiting criteria and other details.
我們有幸邀請到默克中國創新中心高級經理劉靜逸博士和上海交通大學Bio-X研究院的趙祥龍博士，在2月25日周四晚，共同探討類器官晶片在腫瘤藥物研發和臨床精準醫療中的應用。當天，默克也將帶來新一輪默克中國加速器項目的介紹，解答加速器項目招募和申請標準及項目細節。
2/25, Thursday, 7-9 pm
OnePiece Work
7F, 222 Hubin Rd, Link Square 1, Huangpu District - Entrance from Hubin Rd
黃浦區，領展企業天地1號樓7層 - 從湖濱路進入
Scan the QRcode to Register
掃描二維碼註冊
Scan to register the offline event (7-9 PM including networking, wine and light dinner)
掃碼報名線下活動 （晚上7-9點，包含互動，酒水及晚餐）
Register for the online webinar if you cannot attend in person （8-9 PM) :
如果您無法到現場，可通過以下連結或上方二維碼註冊在線觀看（晚上8-9點):
https://zoom.us/meeting/register/tJArfuCsqDkiG9WLreRIvPndf1VgOOyISXxs
7:00PM Networking, wine and light dinner
觀眾註冊，酒水及晚餐
8:00PM Fireside Chat and Q&A
爐邊訪談及問答
9:00PM Discussion and networking
自由互動環節
Dr. Eva Jingyi Liu, Senior Manager, Merck Innovation Hub China
Eva is MD/PhD in Neurology of Clinical Medicine from The Chinese University of Hong Kong, and a Bachelor of Medicine / Bachelor of Surgery degree (MBBS) from Peking University.
She was responsible for strategic investment in BGI, worked on investment deals in pharmaceutical and life science relevant fields like in vitro diagnostics, genetic therapy, cancer immunotherapy, innovation devices and assisted reproductive technology. She was responsible for management consulting & due diligence in IMS/IQVIA, conducted strategic planning for healthcare and life sciences corporates.
She had working experience as a neurologist in Hong Kong Prince of Wales Hospital, Beijing Jishuitan Hospital and New Zealand Auckland City Hospital during MD/PhD study.
In Merck, she is responsible for investment expertise in innovation fields relevant to Merck sectors, and has broad understanding in organoids, IVD and gene and cellular therapy related areas as well.
劉靜逸，醫學博士，默克中國創新中心高級經理
劉靜逸博士擁有香港中文大學醫學院臨床醫學博士學位，北京大學醫學院臨床醫學學士學位。
她曾在華大基因(BGI) 負責戰略投資及併購上市，主導生物製藥及生命科學相關領域的投資/上市交易，包括體外診斷，基因治療，腫瘤細胞免疫治療，創新器械/設備，輔助生殖等。在IMS/IQVIA負責管理諮詢及商業盡調，負責醫療健康及生命科學領域跨國外企戰略規劃，新品上市，政策分析等及醫療投資領域商業盡調。
擁有北京積水潭醫院，香港威爾斯親王醫院，紐西蘭奧克蘭城市醫院神經內科專科臨床醫生工作經驗。
在默克，劉靜逸博士不僅建立了與默克業務相關創新領域的投資專業知識，而且在類器官，體外診斷，基因&細胞治療相關的領域也擁有專業經驗。
Dr. Xianglong Zhao is currently in charge of the establishment of stem cell and organoid platform and organoid chip research at the Personalized Medicine Center (PMC) of Bio-X Institutes of Shanghai Jiaotong University. Before this, he worked at the Gynecology Research Institute of the Third Affiliated Hospital of Guangzhou Medical University's experimental platform, responsible for the management of scientific research teams and interpretation of genetic testing data.
Dr. Zhao is currently a postdoctoral fellow at the Personalized Medicine Center jointly established by Harvard University Broad and Shanghai Jiao Tong University Bio-X Institutes. He has long been engaged in DNA genetics and gene chip related research and participated in publishing 12 Sci papers with a cumulative impact factor of 32. . Currently participating in the international gene database construction project, with a research funding of 4 million US dollars (27.75 million yuan), and has won the Shanghai "Entrepreneurship Qualification Certificate".
The research projects that Dr. Zhao is focused on mainly include: the screening and application of schizophrenia drugs based on organoid chips; application of pharmacogenomics in personalized medicine; market development and clinical application research of domestic genetic testing products.
趙祥龍博士目前在上海交通大學Bio-X研究院個體化醫學中心（PMC）負責幹細胞和類器官平臺建立和類器官晶片研究工作。曾在廣州醫科大學附屬第三醫院婦科研究所實驗平臺，負責科研團隊管理，基因檢測數據解讀工作。
趙博士目前在哈佛大學Broad和上海交通大學Bio-X研究院共建的個體化醫學中心讀博士後，長期從事DNA遺傳學和基因晶片相關領域研究，參與發表Sci論文12篇，累計影響因子32分。目前參與國際基因資料庫構建工程，科研經費400萬美元（2775萬元人民幣），個人榮獲上海市《創業資格證書》。
趙博士負責的研究項目主要有：基於類器官晶片的精神分裂症藥物的篩選和應用；藥物基因組學在個體化醫學中的應用；國內基因檢測產品的市場開發和臨床應用研究等。
About Merck Accelerator
關於默克加速器
The objective of the Accelerator program is to identify promising startups, connect them to relevant business sectors and build pilot projects to foster innovation projects of Merck and its three business sectors for co-development and a sustainable business partnership. The six-month Merck China Accelerator runs once a year with a focus on startups in the seed to series A financing round in the fields of healthcare, performance materials, life sciences, AI-enabled health solutions, organoid, bioelectronics, liquid biopsy, neuromorphic system, and clean meat. The application for the 4th intake of China Accelerator program is open for early application from Jan 25th, 2021, until Feb 25th, 2021. Apply now at 'Read more' at the bottom left of this article or scan the QR code below.
默克加速器項目作為連結默克與初創企業的紐帶，致力於發掘有潛力的初創企業，為他們的業務發展提供支持並建立合作，共同探討和推動為世界創造價值的創新商業機會。為期六個月的默克中國加速器每年進行一期，重點關注醫藥健康、生命科學、高性能材料、人工智慧健康解決方案、類器官、生物電子、液體活檢技術、神經形態系統和清潔肉等領域，處於種子期至A輪融資的初創公司。默克中國加速器第四期已開啟預申請，招募時間為2021年1月25日-2月25日。點擊「閱讀原文」或掃碼立即報名。
About Merck Innovation Hub China
關於默克創新中心
As an important part of Merck’s global innovation network, the China Innovation Hub scouts, incubates and invests in innovative opportunities in healthcare, life science, performance materials and related fields between and beyond the existing businesses. Embedded into China’s innovation ecosystem, Merck Innovation Hub China is committed to partnering with start-ups, academic institutions, industry players and local governments, combining unique technology and expertise from Merck Group and collaborators with the goal to develop novel technology and bring new solutions to the market for China and global. The China Innovation Hub also provides support of ideation, incubation and trainings to local talents, partners and Merck employees to build win-win collaboration. For more information, please visit http://innovateinchina.merckgroup.com.
默克中國創新中心是默克全球創新網絡的一個重要部分，致力於搜尋、孵化和投資醫藥健康、生命科學、高性能材料以及現有業務領域之間和之外的創新機會。默克中國創新中心植根中國創新生態，積極與初創企業、學術機構、業內夥伴和當地政府建立合作夥伴關係，整合默克集團與合作夥伴在各自相關領域的獨特技術和專業技能，開發創新技術，為中國市場和全球業務帶來新的解決方案，同時為本地創新人才、合作夥伴和默克員工提供創意激發培養和創新孵化支持，實現合作共贏。關於默克中國創新中心的更多信息，請訪問http://innovateinchina.merckgroup.com。
About Bio-X Institutes of Shanghai Jiao Tong University
關於上海交通大學Bio-X研究院
The Bio-X Institutes of Shanghai Jiao Tong University was formed in 2005 by merging the Neuropsychiatric and Human Genetics Group (NHGG), which was established in 1996, and the Bio-X Life Science Research Institutes, which was established in April 2000.
The founding of the Bio-X Institutes represents a landmark in interdisciplinary research among the life sciences. The mission of the Institutes is to provide not only an interdisciplinary institute but also to serve as a forum for discussion among scientists and students from a variety of disciplines and fields.
The current director of the Institutes is Prof. Lin He, a fellow of the Chinese Academy of Sciences, and the honorary director is Prof. Steve Zhu, physics Nobel Laureate.
The research at the Bio-X Institutes focuses on interdisciplinary topics between nutrition, health& disease, development and reproduction, biosaftey and DNA computing. More in detail, we currently have research programs in genome mapping and cloning, functional genomics, pharmacogenomics, proteomics, psychiatric metabolism, DNA computing, bioinformatics and nation-wide protection of genetic resources.
上海交通大學Bio-X研究院(以下簡稱「研究院」)是於2005年由NHGG(Neuropsychiatric and Human Genetics Group, 神經精神與人類遺傳學研究室)和2000年成立的Bio-X生命科學研究中心經過重組凝練而成。自從謝繩武校長親自宣布了「研究院」的成立起，標誌了我校正式啟動了生命學科與其他多學科間進行交叉合作研究基地的建設，開始起到成為從事與生命科學相關的多學科交叉研究科學家的工作平臺的作用，並為不同學科和領域的研究人員和學生提供一個學術思想和信息交流的溫馨的「家」。
研究院現屆院長為賀林教授(中國科學院院士)，名譽院長為諾貝爾獎獲得者朱棣文教授。
經過多年的摸索和實踐，最終研究院把自己的研究方向定位在《疾病與健康》、《營養與健康》、《發育與生殖》、《生物安全(籌)》、《DNA計算與技術》的範疇，具體可分解為「基因定位與克隆」、「功能基因組學」、「藥物基因組學」、「精神疾病代謝組學」、「蛋白質組學」、「動物模型」、「DNA計算與技術」、「生物信息學」、「全國遺傳資源保護網」等課題。
Shanghai Caohejing Hi-tech Park Innovation Center was solely invested and run by Shanghai Caohejing Hi-tech Park Development Corporation. As a business incubator, Innovation Center has committed itself to cultivating and supporting technology-intensive enterprises and promoting commercialization, industrialization and internationalization of scientific and technological achievements.
上海漕河涇新興技術開發區科技創業中心（簡稱「創業中心」）是由上海市漕河涇新興技術開發區發展總公司獨資及運營。作為商業孵化器，創業中心致力於孵化及扶持技術為主的企業、並推廣商業化、行業化、國際化的高科成就。
Strategic Partners
戰略合作夥伴
OnePiece Work，2017年誕生於矽谷，是一個新型的跨境創新孵化器。在矽谷、舊金山、洛杉磯、上海、深圳等地設有9個實體空間，提供靈活便捷的辦公租賃服務。
旗下設有早期投資基金UpHonest Capital、矽谷創投自媒體矽兔賽跑，跨境企業資源對接平臺OnePiece Connect等。
我們著眼全球前沿領域，為創新者提供最核心的服務、資源、連結和資金，致力於為全球創新者打造一個完整、開放、共享的創新平臺。
OnePiece Work is a global tech community founded on the idea that together, we can unlock new potential across industries and borders. With innovative workspaces, strategic consulting, and an expert network, we're building a better place for you to work and grow — locally and globally.
Glue Up is an all-in-one CRM platform that helps you build and grow your community through events, memberships & other digital tools.
「Glue Up 未來連結」 是 EventBank 捷會易的全球升級品牌，成立於2013年，創建的初衷是用智能化雲科技幫助活動組織者更好地運營與管理活動。
Startup Grind is the largest independent startup community, actively educating, inspiring, and connecting 1 million entrepreneurs in over 400 cities. In Shanghai, we've been trying to build up a community for entrepreneurs since 2013.
Startup Grind是全球最大的獨立創業社區，在600多個城市中積極地啟蒙、激勵和連接著約200萬名創業者。自2013年來，我們一直努力著在上海為創業者建立起一個社區。
更多精彩信息，
請關注【Startup Grind 上海】官方公眾號:
StartupGrindSH